Survivin-T34A: molecular mechanism and therapeutic potential by Aspe, Jonathan R & Wall, Nathan R
© 2010 Aspe and Wall publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
OncoTargets and Therapy 2010:3 247–254
OncoTargets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
247
RevieW
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/OTT.S15293
Survivin-T34A: molecular mechanism  
and therapeutic potential
Jonathan R Aspe 
Nathan R Wall
Center for Health Disparities 
Research and Molecular Medicine, 
Division of Biochemistry and 
Microbiology, Department of Basic 
Sciences, Loma Linda University,  
Loma Linda, CA, USA
Correspondence: Nathan R Wall 
Center for Health Disparities Research 
and Molecular Medicine, Division 
of Biochemistry and Microbiology, 
Department of Basic Sciences,  
Loma Linda University, 11085 Campus  
Street, Mortensen Hall, Room 162,  
Loma Linda, CA 92350, USA 
Tel +1 909 558 4000 ext 81397 
Fax +1 909 558 0177 
email nwall@llu.edu
Abstract: The inhibitor of apoptosis protein survivin’s threonine 34 to alanine (T34A) 
mutation abolishes a phosphorylation site for p34(cdc2)–cyclin B1, resulting in initiation of the 
mitochondrial apoptotic pathway in cancer cells; however, it has little known direct effects on 
normal cells. The possibility that targeting survivin in this way may provide a novel approach 
for selective cancer gene therapy has yet to be fully evaluated. Although a flurry of work was 
undertaken in the late 1990s and early 2000s, only minor advances on this mutant have recently 
taken place. We recently described that cells generated to express a stable form of the mutant 
protein released this survivin-T34A to the conditioned medium. When this conditioned medium 
was collected and deposited on naive tumor cells, conditioned medium T34A was as effective as 
some chemotherapeutics in the induction of tumor cell apoptosis, and when combined with other 
forms of genotoxic stressors potentiated their killing effects. We hope with this review to revitalize 
the T34A field, as there is still much that needs to be investigated. In addition to determining the 
therapeutic dose and the duration of drug therapy required at the disease site, a better understanding 
of other key factors is also important. These include knowledge of target cell populations, cell-
surface receptors, changes that occur in the target tissue at the molecular and cellular level with 
progression of the disease, and the mechanism and site of therapeutic action.
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Survivin is important in cancer
Apoptosis is a physiological cell suicide program that is critical for the development 
and maintenance of healthy tissues.1 The evasion of apoptosis, as identified by Hanahan 
and Weinberg, is a primary characteristic of human cancer2 with proteins involved in 
its control of significant biological interest, as they could prove to be important targets 
for therapy development. The inhibitor of apoptosis (IAP) family consists of proteins 
with a proven ability to inhibit apoptosis, although much of how this works mecha-
nistically is still to be revealed. Survivin is an important IAP because its expression 
is among the most tumor specific of all human gene products.3,4 It has been classified 
as a bifunctional protein, as it can inhibit apoptosis and cell cycle.5 More specifically, 
survivin’s promoter exhibits M-phase-inducible transactivation and, in HeLa cells, 
both survivin protein and mRNA are upregulated at the G2/M-phase of the cell cycle.5 
Survivin expression is enhanced during embryonic and fetal development but not in 
terminally differentiated normal tissue.6 Its expression has also been seen in virtually 
every type of human cancer,7 making survivin an attractive protein in the study of 
cancer pathophysiology, drug discovery, and medical diagnosis. Our laboratory results 
have recently shown that cancer cells release survivin into the extracellular space8 OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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packaged in small 50–150 nm vesicles called exosomes.9 
This is significant, as it may reveal new mechanisms about 
how cancer cells communicate with one another and how 
they affect the tumor microenvironment. We hope that this 
discovery may provide other options for targeted therapy. 
However, this discovery begs for studies about why and how 
survivin is packaged within exosomes, how survivin from 
exosomes is utilized by the recipient cells, and what are the 
effects of exosomal survivin on normal human cells.
Survivin physically associates with and is phosphory-
lated on its threonine 34 (Thr34) by the cyclin-dependent 
kinase p34(cdc2)–cyclin B1 protein complex.10 Loss 
of Thr34 phosphorylation results in dissociation of the 
caspase-9-  survivin protein complex and caspase-dependent 
apoptosis.10–12 Initially, Thr34 through site-directed muta-
genesis was changed to Ala (T34A) as a nonphosphorylated 
mimic of survivin.10 When replication-deficient adenoviruses 
encoding this survivin-T34A mutant were produced and used 
to infect cancer cell lines, spontaneous apoptosis resulted. 
In contrast, the viability of normal human cells, including 
fibroblasts, endothelium, and smooth muscle cells, was 
unaffected.11 In studies analyzing normal human oral mucosa, 
oral submucosa fibrosis, and oral squamous cell carcinomas,13 
a gradation from no survivin Thr34 phosphorylation in normal 
to significantly enhanced amounts of phosphorylated survivin 
Thr34 in the cancer tissues was recorded. Furthermore, 
phosphorylated Thr34 and p34(cdc2) kinase expression was 
not detected in normal tissue samples but increased with 
advancing stages in the cancer tissue samples.13 Agents that 
elevate p34(cdc2) kinase activity during spindle checkpoint 
activation drive increased survivin expression and cancer cell 
viability,14 resulting in limited anticancer effects. Pharmaco-
logic, genetic, or molecular ablation of p34(cdc2) kinase after 
microtubule stabilization resulted in apoptosis independent 
of p53, suppression of tumor growth, and indefinite survival 
without toxicity in mice.14 Taken together, the ablation of 
survivin-dependent apoptosis inhibition could improve the 
efficacy of many agents used to treat cancer.
One of the most daunting questions in any gene-based 
approach for cancer treatment is in the method of delivery. We 
have recently shown that survivin exists in a novel extracellular 
pool in tumor cells. Furthermore, we have constructed stable 
cell lines that provide the extracellular pool with either wild-
type survivin or dominant-negative mutant survivin (T34A).8 
Cancer cells grown in the conditioned medium taken from 
wild-type survivin-expressing cells absorbed survivin and 
experienced enhanced protection against genotoxic stress 
as well as exhibited an increased replicative and invasive 
potential.8 Alternatively, cancer cells grown in conditioned 
medium from T34A cells began to apoptose through a 
caspase-2- and caspase-9-dependent pathway that was further 
enhanced by the addition of chemo- and radiotherapeutic 
modalities.8 We believe that this extracellular survivin-T34A 
could be used as a possible ‘white knight’ to survivin’s ‘dark 
family’. The following sections detail T34A’s journey as a 
novel potential cancer therapeutic. The aforementioned studies 
have already provided impetus for further studies on T34A, 
but much is still unknown. The advancement of future T34A 
studies may provide a more comprehensive understanding of 
cancer and the potential of using T34A to battle it.
T34A induces apoptosis
What makes this survivin-T34A mutant important as a 
potential therapeutic is that little or no toxicity has resulted 
from its treatment in vitro or in vivo.12,15,16 T34A-treated mice 
showed significantly longer survival rates compared with 
control mice as well as having no pathologic changes in the 
major organs.17 More specifically, tumor cells treated in vitro 
with T34A exhibited reduced cell survival that was associated 
with morphological features of apoptosis.8,11,15,16,18–28 Studies 
of mouse xenographs treated with survivin-T34A concluded 
with significant tumor size reduction and increased animal 
survival rates15–17,19,27 except in mice subcutaneously injected 
with the IGROV1 ovarian carcinoma cell line, where there 
were no significant differences between T34A-infected 
tumors and controls.18 These results may be explained, 
however, as IGROV1 cells do not express significant levels 
of endogenous survivin and T34A, as shown in normal 
survivin-nonexpressing cells, does not induce apoptosis.11 It 
was not until IGROV1 cells were infected with adenovirus 
vector-expressing caspase-3 (Ad-caspase-3) or coinfected 
with Ad-caspase-3 and Ad-T34A that tumor size was reduced 
and survival rates extended.18 It is of much interest that the 
adenoviruses used in these studies upregulated survivin 
mRNA, as shown by reverse transcription-polymerase chain 
reaction, and concomitantly resulted in a half-fold reduc-
tion in another IAP, XIAP (X-linked inhibitor of apoptosis 
protein).18 Furthermore, in melanoma cells that have been 
engineered to express an inducible survivin-T34A,29 XIAP 
and the IAP Livin were cleaved upon T34A induction.20 These 
reductions may in part be responsible for the more favorable 
outcomes observed in these studies. In contrast, it has been 
postulated that the transfection of cells may affect endog-
enous levels of XIAP, but there was no effect on XIAP protein 
levels following transfections using virus vector controls or 
Ad-survivin or Ad-T34A treatment.11,18,20 There were also OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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no changes in other IAPs or members of the Bcl-2 family.20 
Although survivin-T34A may not affect endogenous levels 
of other IAPs, a survivin-IAP (XIAP, cIAP1, and cIAP2) 
complex has been confirmed, as well as a suggestion for direct 
interaction between survivin and XIAP through their BIR 
(baculovirus IAP repeat) domains.30 Furthermore, evidence 
that T34A can only kill cells expressing survivin has been 
shown in its inability to kill normal human cells treated in 
vitro11,31 and in vivo.11,15 However, T34A has shown significant 
killing effects in normal endothelial cells that express high 
levels of endogenous survivin.19 Whether this is the result of 
some interaction between endogenous survivin, other IAPs 
and the T34A mutant, or a competition between them for 
protein interactors is currently unknown.
Mechanistic examination of T34A-induced apoptosis 
revealed mitochondrial events that preceded caspase 
activation, including depolarization and the release of 
cytochrome c, AIF (apoptosis-inducing factor), and Smac/
DIABLO (second mitochondria-derived activator of 
  caspase/direct inhibitor of apoptosis-binding protein with 
low isoelectric point).11,19,20,32 Also, T34A treatment of 
melanoma cells has been shown to involve Apaf-1, Mcl-1, 
and PARP (poly [ADP-ribose] polymerase) cleavage.19,20,25 
Stress-induced cytochrome c release results in apoptosome 
formation and caspase activation;33 thus, several groups have 
reported that caspase-3 may be important to T34A-induced 
apoptosis.11,18–21,26,34 A significant increase in apoptosis was 
reported in ovarian carcinoma cells treated with T34A and 
caspase-3 in vivo and in vitro.18 We, however, when working 
with cervical carcinoma HeLa cells, were unable to show 
cleavage of caspase-3 or caspase-8, though cleavage of 
caspase-9 and caspase-2 was recorded.8 Further experiments 
revealed that T34A induced a reduction in the proforms of 
caspase-2, caspase-7, and caspase-9; a cleavage of PARP; 
and an induction of mitochondrial depolarization. Treatment 
with caspase inhibitors Z-DEVD-FMK and Z-VAD-FMK 
has been shown to counter the effect of T34A treatment, 
suggesting that T34A-induced apoptosis may act through 
the caspase-dependent pathway.20 Additionally, the earliest 
proapoptotic event observed in T34A-treated cells was nuclear 
translocation of mitochondrial AIF, which triggers both 
mitochondrial-associated apoptosis and caspase-  independent 
DNA fragmentation.20 Taken together, survivin-T34A targets 
the intrinsic35 or mitochondria-  associated apoptotic pathway 
to most probably induce caspase-dependent and indepen-
dent apoptosis (Figure 1). However, with the exception of 
one study,36 survivin has not been shown to directly inhibit 
caspases, and whether survivin-T34A disrupts caspase 
activity has yet to be fully elucidated. We postulate that 
survivin-T34A-induced apoptosis begins further upstream 
in the intrinsic apoptotic pathway initiating mitochondrial 
depolarization as well as inhibition of IAPs known to directly 
inhibit caspases (eg, XIAP-caspase-3).
The tumor suppressor gene, p53, has been widely studied 
and is known to induce apoptosis.37,38 As a transcription fac-
tor, p53 is activated by a variety of genotoxic and cytotoxic 
stresses. Upon activation, p53 prevents the proliferation of 
genetically compromised cells by regulating the expression 
of a battery of genes that initiate cell cycle arrest, apoptosis, 
and DNA repair (Figure 2).39 Transcriptionally, p53 activates 
Mdm2, which in turn targets p53 for ubiquitin-proteasome-
dependent degradation. In response to stress, a decrease in 
Mdm2 protein levels and/or its activity and the interaction 
between Mdm2 and p53 lead to p53 stabilization.40 The 
relationship between survivin and p53 may be important, 
as survivin regulates cell division and inhibits apoptosis, 
whereas p53 inhibits cell cycle progression and induces 
apoptosis.21 Survivin was recently shown to be transcription-
ally repressed by wild-type p53, and when overexpressed in 
cells sensitive to p53-dependent cell death markedly inhibited 
apoptosis induced by ultraviolet light.41
When cancer cells that had been stably transfected with 
survivin-T34A were treated with the DNA damage-inducing 
Adriamycin, p53 protein levels were significantly elevated 
compared with DNA damage alone or when combined with 
stably transfected survivin.21 Increased levels of p53 mRNA 
preceded the elevation in p53 protein levels seen with T34A-
treated cells, suggesting that p53 may be directly upregulated 
by survivin-T34A. Survivin disruption by survivin-T34A also 
resulted in the degradation of Mdm2. Proteasome inhibi-
tion and caspase-3 inhibition blocked this survivin-T34A-
associated decrease in Mdm2, resulting in the stabilization 
of p53. Survivin-T34A was not shown to affect mRNA 
levels of Mdm2.21 Furthermore, the p53 homologs TAp63, 
∆Np63, TAp73, and ∆Np73 were analyzed for changes fol-
lowing survivin-T34A treatment. The response of these p53 
homologs is important because TAp63 and TAp73 both trans-
activate similar genes as p53, whereas the ∆Np63 and ∆Np73 
function as antagonists to p53 and the TA homologues.42–44 
∆Np63, TAp73, and ∆Np73 were all decreased in response 
to survivin-T34A, whereas TAp63 was not detectable. These 
findings suggest that p53 transcription may be differentially 
regulated by survivin-T34A.21 Taken together, the ability 
of survivin-T34A to perturb the p53/Mdm2 feedback loop, 
resulting in increasing levels of p53 and p53’s ability to 
then transcriptionally repress survivin, may prove to be just OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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the therapeutic strategy needed for targeting p53-associated 
stress-induced repair pathways in cancer.
Survivin Thr34 plays a role in cell 
cycle regulation
Survivin is a structurally unique IAP family protein that is 
expressed in mitosis in a cell cycle-dependent fashion and 
localized to components of the mitotic apparatus.5 Survivin 
has been described as bifunctional, in that it is involved in 
both inhibition of apoptosis and control of cell division.45,46 
In order to study the effect survivin phosphorylation at 
Thr34 had on cell division, the nonphosphorylatable T34A 
form of survivin was compared with T34E, which acts as 
a phosphomimetic.34 As a phosphomimetic, T34E assumes 
the role of a phosphorylated Thr34 and therefore mimics an 
activated survivin. T34A-treated cells grew two-fold faster 
than control cells, whereas T34E cells grew 2.5-fold slower. 
Depletion studies showed that only T34A was normally 
distributed and able to support cell proliferation, whereas 
T34E was not.
T34A T34A
Caspase-2
Caspase-9
Caspase-3
Caspase-7
Mcl-1
Mitochondrial
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Mitochondria
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Cytochrome C
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Figure 1 Survivin-T34A induces apoptosis by modulating the intrinsic (mitochondrial) pathway of apoptosis. After the mitochondrial depolarization, mitochondrial proteins 
that activate caspases, such as cytochrome c and Smac/Diablo, as well as those that are caspase independent, such as AiF, are released by way of transmembrane channels 
across the mitochondrial outer membrane.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Survivin has been known to be upregulated in G2/M of 
the cell cycle, but T34A’s ability to induce apoptosis is G2/M 
independent.18 The cell cycle profile of T34A-treated cells 
was normal, whereas T34E-treated cells had a significantly 
increased G2/M population, suggesting that cell division 
failed.34 Furthermore, cancer cells that exhibited endogenous 
levels of functional survivin when treated with T34A showed 
significant mitotic index inhibition,11 as well as a reduction in 
colony formation.8 Ultimately, when endogenous survivin was 
depleted, T34A restored survivin’s mitotic function, whereas 
T34E was mitotically incompetent. We therefore conclude 
that phosphorylated Thr34 inhibits mitosis,34 but nonphospho-
rylated survivin is important for mitosis.
T34A has been shown to decrease the proportion of cells 
in S-phase following S-phase arrest.26 Evidence for survivin-
T34A regulation of chromosomal passenger complexes 
and central spindle checkpoint during mitosis has been 
generated.47 In this work, survivin-T34A was also shown to 
be able to restore the spindle checkpoint defect following 
mitosis arrest, unlike the other non-wild-type forms, as well 
as rescue the cells from cytokinesis failure.47 These findings 
strongly suggest that survivin-T34A is a functional comple-
ment for endogenous survivin. Because survivin-T34A 
functionally behaves as survivin, it can localize appropriately 
during mitosis and thus correctly colocalize Aurora B at the 
centromeres and midzone,34,47 allowing proper mitosis regula-
tion. Further experiments show that survivin-T34A correctly 
localizes BubR1 to the kinetochores and can restore localiza-
tion of endogenous Borealin/Dasra B to both centromeres 
and central spindles.48 Taken together, survivin-T34A 
allows for the enhanced proliferative effects of survivin, 
whereas survivin-T34E does not. This suggests that the 
nonphosphorylated survivin Thr34 (T34A) accounts for 
cellular proliferation as opposed to the phosphorylated 
survivin Thr34 (T34E). Also, contrasting survivin Thr34 for 
its cytoprotective activity revealed that T34E is responsible 
for the antiapoptotic characteristics, whereas T34A allows 
for caspase activation and induced apoptosis.34
T34A opposes classical cancer 
characteristics
Angiogenesis is crucial for cell survival and function, and 
without it tumor cells are not able to obtain oxygen and 
nutrients. Targeting tumor angiogenesis is a relatively new 
therapeutic strategy, and it is believed that if the tumor’s 
oxygen and nutrient supply is limited, tumor growth and 
development will be inhibited and may result in apoptosis. 
Survivin-T34A treatment of tumor-bearing mice resulted 
in inhibited tumor-induced angiogenesis and increased 
apoptosis.16,17,27,49 Tumor sections taken from human breast 
cancer transplants in mice were stained with anti-CD31 
antibody to determine microvessel density.50 Survivin-T34A-
treated groups showed significantly reduced microvessel 
density compared with controls.16 In vivo results showed 
T34A-induced apoptotic characteristics in murine endothe-
lial cells as well as decreased new vessel formation when 
compared with control mice.16,19 Furthermore, experiments 
using CT26 colorectal cancer cells showed similar results.17 
It is still unknown how survivin-T34A treatment reduces 
tissue staining for the angiogenesis marker CD31. The 
elucidation of this mechanism may provide insight into this 
tumor-acquired capability. Survivin has been shown to be 
upregulated by vascular endothelial growth factor (VEGF),19 
which is an important promoter of angiogenesis. Perhaps 
survivin regulation by VEGF promotes angiogenesis by 
protecting developing vessels from apoptosis. Therefore, 
survivin-T34A inhibits VEGF’s promotion of angiogenesis, 
which may be mediated through loss of p53, activation of 
phosphatidylinositol 3′-kinase, or phosphorylation of signal 
transducers and activators of transcription 3.51–55
Once a tumor mass becomes constricted, cells acquire the 
ability to invade surrounding tissue and metastasize to distant 
sites, which accounts for 90% of human cancer deaths.2 The 
inhibition of survivin using adenoviruses (Ad-T34A) or short 
hairpin RNA dramatically inhibited invasiveness of prostate 
cancer cells in the in vitro invasion assay and spontaneous 
metastasis in the Dunning prostate cancer in vivo model.56 
Treatment of subcutaneous breast cancer tumors in mice 
Cytotoxic
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Ubiquitin
proteosome
Genotoxic
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DNA
repair
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ATM/ATR
DNA-PK
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Figure  2  Survivin-T34A  promotes  p53-associated  apoptosis.  Upon  activation, 
p53 prevents the proliferation of genetically compromised cells by regulating the 
expression of a battery of genes that initiate cell cycle arrest, apoptosis, and DNA 
repair. Survivin disruption by T34A treatment of cancer cells resulted in increased 
p53 protein levels and proteasomal degradation of Mdm2.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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using T34A plasmids16 or Ad-T34A11 inhibited metastasis 
of breast tumor cells from the primary tumor site to the 
lungs and peritoneum, respectively.16 Specifically, control 
treatment groups were observed to have a greater number of 
metastatic nodules and structural destruction of pulmonary 
alveoli compared with the T34A treatment group in trans-
planted mice.11,16 In light of the role that metastasis plays in 
cancer death, T34A’s metastasis-inhibitory role is important, 
as current therapeutics offer limited capabilities.
Cancerous lesions promote tumor growth, motility, inva-
sion, and angiogenesis via oncogene-driven immunosuppres-
sive leukocyte infiltrates.57 T34A has been shown to enhance 
T-lymphocyte activity against autologous tumor cells.16 In 
addition, T-cells derived from mouse xenographs exhibited 
higher cytotoxicity against target tumor cells in T34A-treated 
mice.17 Further studies revealed that adoptive transfer of 
CD8+ T-lymphocytes, and not their CD4+ T-lymphocyte 
counterparts, isolated from the spleen of T34A-treated mice 
exhibited a decrease in tumor volume. Perhaps the treatment 
of tumor cells with T34A or with immune cells that have 
been primed by survivin-T34A association will redress the 
immunosuppression associated with cancer.
Translational approaches  
and obstacles
Given survivin’s role in chemotherapy and radiation 
resistance,11,12,22,32,58–61 results using T34A would suggest 
that its role is to promote sensitivity to chemotherapy and 
radiotherapy. In the first study to investigate T34A’s abil-
ity to enhance cancer cell chemosensitivity, transfected 
survivin-T34A-induced apoptosis was as effective as Taxol 
alone, whereas transfected survivin-T34A cells enhanced 
Taxol-induced apoptosis.11 Subsequent studies involving 
other chemotherapeutics have also revealed enhanced apop-
tosis in T34A-expressing cancer cells and xenograph models 
(Flutamide,59 Paclitaxel22). Survivin-T34A combined with 
Adriamycin exhibited no added effect over Adriamycin 
alone.11 This study was followed by studies designed to 
characterize phosphorylated survivin Thr34’s protective role. 
Following Adriamycin treatment of tumor cells, p34(cdc2) 
was coimmunoprecipitated with survivin. These findings sug-
gest that p34(cdc2) phosphorylates survivin on Thr34 following 
Adriamycin treatment thus protects the cells against the che-
motherapeutic. These results were correlated with elevated 
MPM-2 mitotic phosphoepitope expression.12 Although 
survivin-T34A combined with Adriamycin exhibited no 
added effect over Adriamycin alone, it may still be possible to 
synergistically enhance Adriamycin’s effect with pretreatment 
of survivin-T34A. The same study further showed that 
increased doses of Flavopiridol treatment were associated 
with suppression of survivin Thr34 phosphorylation.
Human glioblastoma multiforme (GBM) cells were 
treated with adenoviral vectors containing T34A or survivin 
in vivo and in vitro. No change was seen in normal cells 
treated with either survivin form, but radiosensitivity was 
exhibited in T34A-treated cells compared with survivin-
treated or control cells. Several other studies have confirmed 
similar results, suggesting that survivin only affects the 
radiosensitivity of tumors cells and that radioresistance can 
be reduced by T34A treatment.8,32,34,61,62 Interestingly, when 
cancer cells were irradiated and then treated with T34A, 
radiosensitivity was enhanced even more.58 Enhanced radia-
tion sensitivity may be explained by cleavage and activation 
of caspase-3 in T34A-treated cells. Caspase inhibitors, except 
those for caspase-9, have been able to reduce apoptotic 
phenotypes in X-irradiation of T34A-treated cells.32 Radio-
sensitivity may also be induced via a caspase-independent 
mechanism.58 DNA double strand breakage was greater in 
T34A-treated cells, suggesting that T34A may interfere with 
the cells’ ability for DNA repair postirradiation.58
Conclusion
Survivin-T34A has a rich history, having first been utilized as a 
mimic of nonphosphorylated survivin and now as a possible 
cancer therapeutic. It has potential in molecular therapy 
because of its minimal toxicity and its ability to induce apop-
tosis and immune modulation while reducing angiogenesis, 
metastasis, and cell cycle progression in survivin-expressing 
cells (Figure 3). With the discovery that a T34A-conditioned 
medium taken from cells that overexpress and release 
  survivin-T34A to the extracellular space is able to kill cancer 
cells in vitro,8 we hope to further enhance the scientific 
data banks and pave new paths for clinical modalities and 
regimens. For this to occur, however, additional testing of this 
agent on normal tissues, specifically testing its ‘myelosup-
pressive effects’, will have to be completed. Also, additional 
studies to synergistically enhance chemo- and radiotherapies, 
whether in combination with or through survivin-T34A pre-
treatment, must be accomplished. The knowledge that will 
make this possible includes the elucidation of survivin-T34A 
target cell populations, cell-surface receptors, changes that 
occur in the target tissue at the molecular and cellular level, 
the presence or development of resistance that could limit 
its use, the mechanism of therapeutic action, and its site of 
action. As survivin and p53 are important opposing regulators 
of cancer, further research on their interactions and signaling OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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pathways will likely provide specific clues for understanding 
this complicated relationship.
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